You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • S99 Efficacy of nintedanib on acute exacerbations reported as serious adverse events in the inpulsis® trials in idiopathic pulmonary fibrosis (IPF)

Article info

Article menu

Download PDFPDF

Idiopathic Pulmonary Fibrosis Therapy
S99 Efficacy of nintedanib on acute exacerbations reported as serious adverse events in the inpulsis® trials in idiopathic pulmonary fibrosis (IPF)
Free

Authors

Citation

Richeldi L, Koegler H, Trampisch M, et al
S99 Efficacy of nintedanib on acute exacerbations reported as serious adverse events in the inpulsis® trials in idiopathic pulmonary fibrosis (IPF)
Thorax 2016;71:A58-A59.

Publication history

  • First published November 15, 2016.
Online issue publication 
September 01, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions